



Symbicort® (budesonide/formoterol) – First-time authorized brand alternative

- On January 3, 2020, [Prasco launched](#) an authorized brand alternative of [Symbicort \(budesonide/formoterol\)](#) inhalation.
- Symbicort is approved for the treatment of asthma in patients 6 years of age and older and for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and/or emphysema.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.